Independent international patient coordinationA specialist service by Access China Med
Patient guide

Clinical trial vs clinical application in China

Understand the difference between registered research, drug development and clinical application before considering regenerative medicine in China.

Clinical research has a different purpose

A clinical trial or other registered clinical study is designed to answer research questions under a protocol. Participation may offer access to an investigational intervention, but the main purpose is to generate knowledge about safety, dose, feasibility or efficacy.

Patients must meet inclusion and exclusion criteria, understand randomisation or control groups where relevant, and give informed consent. Recruitment status can change.

Clinical application is not the same as a trial

A clinical application pathway is intended for clinical use under a defined authorisation and institution. It may still have eligibility requirements, evidence limitations and post-use monitoring. It should not be described with the same language as research participation.

Drug and medical-device trials are another route

Cell products may also be developed as drugs through formal regulatory clinical trials. These studies follow product-development rules and may progress through phase I, II and III before marketing authorisation. A phase II result does not mean the product is routinely available.

Research-related costs should be explained clearly. China’s 2026 biomedical-new-technology regulation states that clinical-research institutions must not charge participants fees related to that research. Patients may still have ordinary medical or travel expenses, but these should not be disguised as a price for trial participation.

How to evaluate a trial opportunity

  • Registry number and official title
  • Sponsor, responsible institution and principal investigator
  • Recruitment status and location
  • Study phase, intervention and comparator
  • Inclusion and exclusion criteria
  • Known risks and monitoring
  • Travel, follow-up and language requirements
  • What care and costs are covered

How we support trial matching

We can identify potentially relevant registered studies and help prepare a concise enquiry, but the study team decides eligibility. We do not sell trial placement or guarantee enrolment.

Frequently asked

Questions about this topic

No legitimate study should guarantee enrolment in exchange for payment. The protocol and study team determine eligibility.

No. Phase III is a stage of clinical development. Marketing or routine clinical access may still require further review and authorisation.

Some may, while others may not. Language, residency, follow-up and protocol criteria can affect access.

Not necessarily. Some trials use randomisation, comparison groups or blinding.

The protocol may require observation and repeated follow-up. Travel plans must fit the study schedule.

The consent documents and study arrangements should explain medical care, compensation and insurance. Ask the study team directly.

Medical assessment

Start with a confidential case summary

Tell us your diagnosis, current treatment and main goal. We will first check whether a credible pathway may justify formal hospital review.

Submit Your Case